| | HDFC Balanced Adv Direct Plan Dividend Payout Opti | 0P0001. | 44.053 | +0.66% | 798.75B | 08/05 | |
| | HDFC Balanced Advantage Fund Growth | 0P0001. | 465.638 | +0.66% | 798.75B | 08/05 | |
| | ICICI Prudential Balanced Advantage Fund Direct Pl | 0P0001. | 18.080 | 0% | 561.75B | 27/10 | |
| | ICICI Prudential Balanced Advantage Fund Dividend | 0P0000. | 17.950 | +0.17% | 561.75B | 08/05 | |
| | ICICI Prudential Balanced Advantage Fund Growth | 0P0000. | 64.760 | +0.22% | 561.75B | 08/05 | |
| | ICICI Prudential Balanced Advantage Fund Direct Pl | 0P0000. | 27.180 | +0.22% | 561.75B | 08/05 | |
| | ICICI Prudential Balanced Advantage Fund Monthly D | 0P0000. | 20.370 | -0.10% | 561.75B | 08/05 | |
| | ICICI Prudential Balanced Advantage Fund Direct Pl | 0P0000. | 71.730 | +0.21% | 561.75B | 08/05 | |
| | ICICI Prudential Balanced Advantage Fund Direct Pl | 0P0000. | 23.950 | -0.08% | 561.75B | 08/05 | |
| | Kotak Balanced Advantage Fund Direct Growth | 0P0001. | 19.401 | +0.26% | 157.21B | 08/05 | |
| | Kotak Balanced Advantage Fund Regular Growth | 0P0001. | 18.123 | +0.25% | 157.21B | 08/05 | |
| | Edelweiss Balanced Advantage Fund Regular Plan Gro | 0P0000. | 46.470 | +0.37% | 107.38B | 08/05 | |
| | Edelweiss Balanced Advantage Fund Direct Plan Grow | 0P0000. | 52.110 | +0.37% | 107.38B | 08/05 | |
| | Tata Balanced Advantage Fund Regular Growth | 0P0001. | 18.858 | +0.24% | 91.07B | 08/05 | |
| | Reliance NRI Equity Fund - Direct Plan - Dividend | 0P0000. | 43.856 | +0.28% | 79.28B | 08/05 | |
| | Reliance Balanced Advantage Fund - Growth | 0P0000. | 158.366 | +0.27% | 79.28B | 08/05 | |
| | Reliance NRI Equity Fund - Direct Plan - Growth Pl | 0P0000. | 176.856 | +0.27% | 79.28B | 08/05 | |
| | Aditya Birla Sun Life Balanced Advantage Fund Dire | 0P0000. | 103.710 | +0.11% | 70.62B | 08/05 | |
| | Aditya Birla Sun Life Balanced Advantage Fund Divi | 0P0000. | 25.320 | +0.08% | 70.62B | 08/05 | |
| | Aditya Birla Sun Life Balanced Advantage Fund Grow | 0P0000. | 92.580 | +0.10% | 70.62B | 08/05 | |
![[포스트IPO] ‘세포분석공정 자동화’ 표준화 선도에 신제품까지…큐리옥스, 성장 로드맵 ‘착착’](https://i-invdn-com.investing.com/news/external-images-thumbnails/picdb76cc1e2e5fcd29190023c675b092e5.png)
![[0509섹터분석] 중국 소비주, 의료기기 테마 강세! 2차전지 테마 하락](https://i-invdn-com.investing.com/news/external-images-thumbnails/pic4f184e7582957a97a5f669fdbd7cb076.png)
